# Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

> **NCT00623649** · PHASE1 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 42 (actual)

## Conditions studied

- HCV Infection

## Interventions

- **DRUG:** VCH 916
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00623649
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2014-04-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623649, "Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00623649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*